On August 24, Moderna, Inc. rose 4.66% overnight, trading at $152.39/share with turnover of $9.15 million, as the stock continues to stabilize following its historic 177% single-day surge on August 19 and subsequent volatility.

The ongoing positive momentum stems from the company's landmark announcement with Merck that their personalized mRNA cancer vaccine intismeran autogene achieved primary and key secondary endpoints in the Phase III INTerpath-001 trial for high-risk melanoma patients, marking the first-ever positive Phase III result for a personalized mRNA cancer therapy. Following the initial surge and a 23% profit-taking pullback, multiple Wall Street firms issued significant upgrades: BofA raised its rating to Neutral with a target of $170 from $40, Piper Sandler set a $167 target maintaining Overweight, JPMorgan raised to $77, Goldman Sachs lifted to $120, and William Blair upgraded to Outperform. Options market data showed bullish large-block positioning with implied volatility at the 99.6th percentile, indicating sustained institutional interest.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)